Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Clonazepam, ATC N03AE01 für die Zeit 01.08.2026 - 31.07.2028 (zzgl. Verlängerungsoption 1x12 Monate)

This is a non-exclusive discount agreement (Rabattvereinbarung) under §130a Abs. 8 SGB V for the active substance Clonazepam (ATC N03AE01), published by DAK-Gesundheit in Germany. The procedure is an 'open house' model allowing any pharmaceutical company to join at any time during the contract period (01.08.2026-31.07.2028 with a 1x12-month renewal option). The estimated value of 1 EUR is symbolic and does not reflect actual volume. The contract automatically terminates if an exclusive agreement is concluded. Submission is only via email in German, with no formal award criteria as all qualified participants are accepted. Procurement documents are available but were not analyzed in detail.